Janux Therapeutics (JANX) Insider Trading & Ownership $59.61 -1.95 (-3.17%) (As of 12/17/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Janux Therapeutics (NASDAQ:JANX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage29.40%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$53.70 MNumber OfInsiders Selling(Last 12 Months)5Amount OfInsider Selling(Last 12 Months)$185.83 M Get JANX Insider Trade Alerts Want to know when executives and insiders are buying or selling Janux Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address JANX Insider Buying and Selling by Quarter Ad Porter & CompanyI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. Janux Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails12/3/2024David Alan CampbellCEOSell15,000$67.00$1,005,000.00 11/25/2024David Alan CampbellCEOSell25,000$51.60$1,290,000.00 10/28/2024David Alan CampbellCEOSell25,000$53.54$1,338,500.00 10/18/2024Ra Capital Management, L.P.DirectorBuy1,200,000$44.75$53,700,000.00 10/17/2024Ventures Xi L.P. AvalonMajor ShareholderSell1,843$50.02$92,186.86 9/30/2024Ventures Xi L.P. AvalonMajor ShareholderSell958$46.24$44,297.92 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 9/27/2024Andrew Hollman MeyerInsiderSell50,000$45.96$2,298,000.00 9/27/2024David Alan CampbellCEOSell25,000$46.31$1,157,750.00 9/27/2024Ventures Xi L.P. AvalonMajor ShareholderSell49,231$46.45$2,286,779.95 9/12/2024Ventures Xi L.P. AvalonMajor ShareholderSell158,031$47.00$7,427,457.00 9/9/2024Ventures Xi L.P. AvalonMajor ShareholderSell2,182$42.33$92,364.06 9/6/2024Ventures Xi L.P. AvalonMajor ShareholderSell108,365$42.00$4,551,330.00 6/3/2024Jay LichterDirectorSell1,500,000$54.75$82,125,000.00 6/3/2024Tighe ReardonCFOSell822,721$54.75$45,043,974.75 6/3/2024Ventures Xi L.P. AvalonMajor ShareholderSell677,279$54.75$37,081,025.25 (Data available from 1/1/2013 forward) JANX Insider Trading Activity - Frequently Asked Questions Who is on Janux Therapeutics's Insider Roster? The list of insiders at Janux Therapeutics includes Andrew Hollman Meyer, David Alan Campbell, Jay Lichter, Ra Capital Management, L.P., Tighe Reardon, and Ventures Xi L.P. Avalon. Learn more on insiders at JANX. What percentage of Janux Therapeutics stock is owned by insiders? 29.40% of Janux Therapeutics stock is owned by insiders. Learn more on JANX's insider holdings. Which Janux Therapeutics insiders have been buying company stock? The following insiders have purchased JANX shares in the last 24 months: Ra Capital Management, L.P. ($59,867,799.68), and Ventures Xi L.P. Avalon ($4,988,642.98). How much insider buying is happening at Janux Therapeutics? Insiders have purchased a total of 2,544,862 JANX shares in the last 24 months for a total of $64,856,442.66 bought. Which Janux Therapeutics insiders have been selling company stock? The following insiders have sold JANX shares in the last 24 months: Andrew Hollman Meyer ($2,298,000.00), David Alan Campbell ($4,791,250.00), Jay Lichter ($82,125,000.00), Tighe Reardon ($45,043,974.75), and Ventures Xi L.P. Avalon ($51,575,441.04). How much insider selling is happening at Janux Therapeutics? Insiders have sold a total of 3,460,610 Janux Therapeutics shares in the last 24 months for a total of $185,833,665.79 sold. Janux Therapeutics Key ExecutivesDr. David Alan Campbell Ph.D. (Age 64)President, CEO & Director Compensation: $1.04MMr. Charles M. Winter (Age 55)Chief Technical Officer Compensation: $590.4kMr. Byron Robinson J.D. (Age 59)Ph.D., Chief Strategy Officer Compensation: $723kMr. Tighe M. Reardon C.F.A. (Age 48)CPA, Acting Chief Financial Officer Dr. Tommy Diraimondo Ph.D. (Age 38)Chief Scientific Officer Mr. James PenningtonGeneral CounselMs. Brenda Van VreeswykHead of Human ResourcesMr. Andy Hollman Meyer (Age 40)Chief Business Officer 1 recent trades More Insider Trading Tools from MarketBeat Related Companies SRPT Insider Buying CTLT Insider Buying PCVX Insider Buying ITCI Insider Buying ROIV Insider Buying RVMD Insider Buying LNTH Insider Buying NUVL Insider Buying BPMC Insider Buying ELAN Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles AppLovin Insiders Sell Shares: Stock Price Indicated Higher Are 2024’s Top Insider Buys a Good Bet for 2025? Bargains Galore? 3 Stocks With Insider Buying in the MillionsInsiders Keep Buying These Stocks: 2 to Buy, 1 to AvoidZeta Global Holdings Insiders Buy Stock After Short-Report This page (NASDAQ:JANX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janux Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Janux Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
